About: The influence of pharmacogenetic and pharmacokinetic factors on the efficacy and safety of the first schizophrenia episodes therapy     Goto   Sponge   NotDistinct   Permalink

An Entity of Type : http://linked.opendata.cz/ontology/domain/vavai/Projekt, within Data Space : linked.opendata.cz associated with source document(s)

AttributesValues
rdf:type
Description
  • Jedná se o aplikovaný výzkum v oblasti farmakogenetiky a farmakokinetiky. Bude zjišťováno, zda úspěšnost a bezpečnost léčby prvních epizod schizofrenie risperidonem souvisí s fenotypem a genotypem 2D6 izoformy cytochromu P450 (CYP2D6). Do projektu bude zařazeno 25-30 pacientů (dle možností) s první epizodou schizofrenie, kteří budou léčeni risperidonem. Fenotyp CYP2D6 bude zjišťován na počátku, v průběhu a na konci terapie a genotyp 1x při zařazení do studie. V průběhu a ke konci terapie budou sledovány parametry úspěšnosti a bezpečnosti (např. výskyt nežádoucích účinků) terapie. Tyto parametry budou následně statisticky vyhodnoceny s ohledem na příslušnost ke genotypu / fenotypu pacientů a budou vytipováni pacienti s rizikem výskytu nežádoucích účinků a pacienti - nonrespondéři. (cs)
  • The project is focused on the research in the field of clinical pharmacokinetics and pharmacogenetics. The project is going to clarify the relationship between the phenotype/genotype and effectiveness and occurence of adverse effects of the risperidone therapy in the first episodes of schizophrenia. In the project, 25 (up to 30) patients with the first attack of schizophrenia treated with risperidone will be included in the study. Phenotype of CYP2D6 will be assessed at the beginning of the study, in the course, and finally at the end of hospitalization; genotype will be determined once during the hospitalization. Parameters of the effectiveness and safety will be assessed continuously during the hospitalization. Consecutively, these parameters will be statistically evaluated with respect to the assessed genotype/phenotype of CYP2D6. Patients with higher risk of adverse effects and patients-nonresponders will be found out. (en)
Title
  • The influence of pharmacogenetic and pharmacokinetic factors on the efficacy and safety of the first schizophrenia episodes therapy (en)
  • Vliv farmakogenetických a farmakokinetických faktorů na účinnost a bezpečnost terapie prvních epizod schizofrenie (cs)
http://linked.open...vai/cislo-smlouvy
http://linked.open...avai/druh-souteze
http://linked.open...domain/vavai/faze
http://linked.open...vavai/hlavni-obor
http://linked.open...vai/vedlejsi-obor
http://linked.open...vavai/id-aktivity
http://linked.open.../vavai/id-souteze
http://linked.open...n/vavai/kategorie
http://linked.open...vai/klicova-slova
  • genotype; phenotype; cytochrome; CYP2D6; schizophrenia; risperidone; effectiveness; safety (en)
http://linked.open...avai/konec-reseni
http://linked.open...nujicich-prijemcu
http://linked.open...avai/poskytovatel
http://linked.open...avai/start-reseni
http://linked.open...ai/statni-podpora
http://linked.open...vavai/typProjektu
http://linked.open...ai/uznane-naklady
http://linked.open...ai/pocet-prijemcu
http://linked.open...cet-spoluprijemcu
http://linked.open...ai/pocet-vysledku
http://linked.open...ku-zverejnovanych
is http://linked.open...ain/vavai/projekt of
Faceted Search & Find service v1.16.118 as of Jun 21 2024


Alternative Linked Data Documents: ODE     Content Formats:   [cxml] [csv]     RDF   [text] [turtle] [ld+json] [rdf+json] [rdf+xml]     ODATA   [atom+xml] [odata+json]     Microdata   [microdata+json] [html]    About   
This material is Open Knowledge   W3C Semantic Web Technology [RDF Data] Valid XHTML + RDFa
OpenLink Virtuoso version 07.20.3240 as of Jun 21 2024, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (126 GB total memory, 120 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software